Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
the 1.0 mL was given to a pediatric patient; the 1.0 mL was given to a pediatric patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 15-month-old male patient who received HAV (Havrix adult) for prophylaxis. On 13-MAR-2025, the patient received the 1st dose of Havrix adult. On 13-MAR-2025, an unknown time after receiving Havrix adult, the patient experienced adult product administered to child (Verbatim: the 1.0 mL was given to a pediatric patient) and overdose (Verbatim: the 1.0 mL was given to a pediatric patient). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-MAR-2025 A Registered Nurse called just to have some information an adult Hepatitis A vaccine, and reported that the 1.0 milliliter of Havrix (adult dose) was given to a pediatric patient which led to adult product administered to child and overdose. She just wanted, kind of get more information, other than potential increase of local reactions is there anything else that we need to be aware of.